Glassroth Jeffrey
University of Wisconsin-Madison, Department of Medicine, 600 Highland Avenue, J5/219, Madison, Wisconsin 53714, USA.
Trans Am Clin Climatol Assoc. 2005;116:293-308; discussion 308-10.
Tuberculosis (TB) continues as a major public health challenge worldwide. HIV-TB coinfection is especially concerning as it accelerates progression of infection to active disease and amplifies spread of TB including drug resistant disease. Application of molecular biology and insights from classic microbiology to TB control have resulted in important innovations in diagnosis and treatment. Radiometric assay and, particularly, PCR, with nucleic acid probing, have reduced the time to diagnosis. Moreover, the sensitivity of these techniques is potentially log orders of magnitude more sensitive. Molecular techniques can be adapted to drug susceptibility testing. The differential activity and post-antibiotic effect of various drugs against TB have led to highly effective briefer regimens and to directly observed therapy. Insights into basic host defense against TB and description of the M. tuberculosis genome have created optimism for developing new treatments and effective vaccines in the years to come.
结核病仍是全球主要的公共卫生挑战。艾滋病毒与结核病合并感染尤其令人担忧,因为它会加速感染向活动性疾病的进展,并加剧结核病(包括耐药性疾病)的传播。将分子生物学及经典微生物学的见解应用于结核病防控,已在诊断和治疗方面带来了重要创新。放射测量法,尤其是聚合酶链反应(PCR)结合核酸探针技术,缩短了诊断时间。此外,这些技术的灵敏度可能提高了几个数量级。分子技术可用于药物敏感性测试。各种药物对结核病的不同活性及抗生素后效应,已促成了高效的短程治疗方案以及直接观察治疗法。对宿主抗结核病基本防御机制的深入了解以及结核分枝杆菌基因组的描述,让人们对在未来几年开发新的治疗方法和有效的疫苗充满信心。